Predictmedix Announces Private Placement
Predictmedix Announces Private Placement
TORONTO, ON / ACCESSWIRE / June 16, 2023 / Predictmedix Inc. ("Predictmedix" or the "Company") (CSE:PMED)(OTCQB:PMEDF), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI), announces a proposed private placement. The Company intends to issue 10,510,000 units (the "Units") at a price of $0.10 per unit to investors for gross proceeds of $1,051,100. Each Unit will consist of one common share of the Company and one common share purchase warrant (a "Warrant"), whereby each Warrant entitles the holder to purchase one additional common share for a period of two years from closing at an exercise price of $0.15 per share.
多伦多,2023年6月16日/ACCESSWIRE/由专有人工智能(AI)支持的快速健康筛查解决方案的领先提供商Predidicmedix Inc.(以下称PredicicMedix或公司)(CSE:PMEd)(场外交易市场代码:PMEDF)宣布了一项私募计划。公司拟以每单位0.10美元的价格向投资者发行10,510,000个单位(“单位”),总收益为1,051,100美元。每个单位将由一股本公司普通股及一份普通股认购权证(“认股权证”)组成,据此,每份认股权证持有人有权在两年内按每股0.15美元的行使价购买额外一股普通股。
The Company expects to close the private placement next week. Net proceeds will be used for general operations (working capital) including business development and technology upgrades. All securities issued in connection with the private placement will be subject to a statutory hold period expiring four months and one day from the date of issuance of the securities.
该公司预计将于下周完成私募。净收益将用于一般业务(营运资金),包括业务发展和技术升级。所有与私人配售有关而发行的证券,均须受自证券发行日期起计四个月零一天的法定持有期所规限。
About Predictmedix Inc.
关于Predicate Medix Inc.
Predictmedix (CSE:PMED)(OTCQB:PMEDF)(FRA3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.
普瑞医疗(CSE:PMED)(OTCQB:PMEDF)(FRA3QP)是一家新兴的全球快速健康筛查和远程患者护理解决方案提供商。该公司的安全入口站由专有人工智能(AI)提供支持,使用多光谱相机分析生理数据模式并预测各种健康问题,包括传染病(如新冠肺炎)、药物或酒精损害、疲劳或各种精神疾病。PredidicMedix专有的远程患者护理平台为医疗专业人员提供了一套人工智能支持的工具,以改善患者的健康状况。要了解更多信息,请访问我们的网站,或在Twitter、Instagram或LinkedIn上关注我们。
Public Relations Contact
公共关系联系人
For further media information or to set up an interview, please contact:
欲了解更多媒体信息或安排采访,请联系:
Nelson Hudes
Hudes Communications International
(905) 660 9155
Nelson@hudescommunications.com
纳尔逊·胡德斯
哈迪斯国际通信公司
(905)660 9155
邮箱:nelson@hudesCommunication ations.com
Dr. Rahul Kushwah
(647) 889 6916
拉胡尔·库什瓦博士
(647)889 6916
Caution Regarding Forward-Looking Information:
有关前瞻性信息的警告:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.
本新闻稿可能包含基于当前预期的前瞻性陈述和信息。这些声明不应被解读为对公司未来业绩或结果的保证。这类陈述涉及已知和未知的风险、不确定因素和其他因素,可能导致实际结果、业绩或成就与这类陈述所暗示的大不相同。虽然这些陈述是基于管理层的合理假设,但不能保证这些假设将被证明是正确的。我们不承担更新或修改它们以反映新事件或新情况的责任。本公司的证券尚未根据修订后的《1933年美国证券法》(下称《美国证券法》)或适用的州证券法进行注册,除非进行注册或获得适用的豁免,否则不得向美国境内的人或美国人提供或出售,或为美国境内的人或“美国人”的账户或为他们的利益服务。本新闻稿不应构成出售要约或征求购买要约,也不应在美国或任何司法管辖区出售任何此类要约、征求或出售将是非法的证券。此外,存在已知和未知的风险因素,可能导致公司的实际结果、业绩或成就与本文包含的前瞻性信息明示或暗示的未来结果、业绩或成就的第4页存在实质性差异,这些风险因素包括但不限于对获得监管部门批准的依赖;获得与其技术相关的知识产权的能力;有限的经营历史;一般的商业、经济、竞争、政治、监管和社会不确定性,尤其是与新冠肺炎相关的不确定性;与公司无法控制的因素相关的风险,包括与新冠肺炎相关的风险;与公司股票相关的风险,包括可能或可能不在该方控制范围内的事件导致的价格波动;对管理层的依赖;以及行业中更多竞争对手的紧急情况。
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
本文中的所有前瞻性信息都受本警示声明的约束,公司没有义务修改或更新任何此类前瞻性信息,也没有义务公开宣布对本文中包含的任何前瞻性信息的任何修改结果,以反映未来的结果、事件或发展,除非法律要求。
Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."
免责声明:“本公司目前不会明示或暗示其产品有能力诊断、消除、治愈或控制新冠肺炎(或SARS-2冠状病毒)。”
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
加拿大证券交易所尚未对本新闻稿的充分性或准确性进行审查,也不承担任何责任。
SOURCE: PredictMedix Inc.
资料来源:PredidicMedex Inc.